Sugi Predict

Sugi Predict / Compounds / SCHEMBL18575864

SCHEMBL18575864

SCHEMBL18575864

CN[C@@H](CCC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PPARA Q07869 4/20 0.38
▸ PPARG P37231 3/20 0.38
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ FOLH1 Q04609 1/20 0.36
▸ RIMKLA Q8IXN7 1/20 0.36
▸ NAALAD2 Q9Y3Q0 1/20 0.36
▸ P2RY12 Q9H244 5/20 0.35
▸ GGH Q92820 1/20 0.35
▸ ACE P12821 1/20 0.35
▸ CYP2D6 P10635 1/20 0.34
▸ CTSK P43235 2/20 0.34
▸ PPARD Q03181 2/20 0.34
▸ CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13876903 1.00 MEN1 (0.40) MEN1GAAKMT2APPARAPPARG
Ammonia Solution, Strong SCHEMBL28163206 0.98 MEN1 (0.39) MEN1GAAKMT2APPARAPPARG
SCHEMBL8360180 0.87 MEN1 (0.40) MEN1GAAKMT2APPARAPPARG
SCHEMBL18575981 0.86 MEN1 (0.35) MEN1GAAKMT2APPARAPPARG
SCHEMBL17177654 0.86 KMT2A (0.40) MEN1GAAKMT2APPARAPPARG
SCHEMBL9086263 0.86 L3MBTL1 (0.37) MEN1GAAKMT2AHDAC3HDAC1
SCHEMBL17178074 0.86 CYP2D6 (0.34) MEN1GAAKMT2AHDAC3HDAC1
SCHEMBL5400659 0.85 MEN1 (0.37) MEN1GAAKMT2APPARAPPARG
SCHEMBL4371936 0.84 FOLH1 (0.43) MEN1GAAKMT2APPARAPPARG
SCHEMBL23901540 0.84 CTSK (0.33) MEN1GAAKMT2AHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240871-B2 Method for producing peptide compound NISSAN CHEMICAL CORPORATION (JP) 2025-03-04 — — US disclosed
US-20240199692-A1 POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT TAISHO PHARMACEUTICAL CO., LTD. (JP) 2024-06-20 — — US disclosed
WO-2023204170-A1 PROPHYLACTIC OR THERAPEUTIC AGENT, FOR LUNG INFLAMMATION AND FIBROSIS, CONTAINING COMPOUND HAVING MMP2 INHIBITORY ACTIVITY AS ACTIVE INGREDIENT 大正製薬株式会社 2023-10-26 — — WO disclosed
US-20230295221-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-21 — — US disclosed
EP-4144747-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-03-08 — — EP disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 — — US disclosed
EP-4056581-A1 POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT Taisho Pharmaceutical Co., Ltd. (JP) 2022-09-14 — — EP disclosed
US-20220153777-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2022-05-19 — — US disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 — — US disclosed
WO-2021067439-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-08 — — WO disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 — — US disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 — — US disclosed
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus SEATTLE GENETICS, INC. (US) 2018-06-19 — — US disclosed
WO-2017035501-A1 SIALYLTRANSFERASE INHIBITORS AND USES THEREOF ACADEMIA SINICA (TW) 2017-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199692-A1 POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT MMP2, MMP26, MMP25 MEN1 583/4885GAA 704/4885KMT2A 3722/4885
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR MEN1 3914/4885GAA 1820/4885KMT2A 4739/4885
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR MEN1 3914/4885GAA 1820/4885KMT2A 4739/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR MEN1 3914/4885GAA 1820/4885KMT2A 4739/4885
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR MEN1 3914/4885GAA 1820/4885KMT2A 4739/4885
US-12240871-B2 Method for producing peptide compound NGLY1, NPPA, NPEPPS MEN1 143/4885GAA 2690/4885KMT2A 3924/4885
US-20230295221-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES NGLY1, VIP, DNPEP MEN1 209/4885GAA 2354/4885KMT2A 3727/4885
US-20220153777-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND NGLY1, NPPA, NPEPPS MEN1 143/4885GAA 2690/4885KMT2A 3924/4885
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus PTMS, MMAB, DNPEP MEN1 130/4885GAA 1242/4885KMT2A 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.